Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden

In this article, published in Future Oncology, researchers from Sweden and Switzerland have investigated the pattern of implementation of subcutaneous trastuzumab and the switching rate between the two formulations in a real-world setting using data from three nonacademic hospitals in Sweden. Trastuzumab, a humanized anti-HER2 monoclonal antibody, has changed the natural history of HER2-positive breast cancer from an aggressive disease with poor prognosis to a disease with comparable outcome to HER2-negative breast cancer. As a result, trastuzumab is the cornerstone of treatment strategy in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic setting. Trastuzumab is available in...